Rumors that Celgene Corporation is in talks to acquire Juno Therapeutics has caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
Juno Therapeutics said that it will end development of the experimental CAR-T therapy JCAR015 in adults with relapsed or refractory acute lymphoblastic leukaemia (ALL) following safety issues observed in a mid-stage trial.